Avantor, Inc.

NYSE:AVTR

Medical - Instruments & Supplies

Healthcare
$15.37 +0.69%

+$0.07 today

Market cap
$10.41B
Beta
0.96
P/E (TTM)
-11.7
EPS (TTM)
-$0.81
52W Low $7.27High $15.93

Volume 5.94M

Average 9.44M

AVTR Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Avantor, Inc.NYSE: AVTR

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income declines year over year

Q2 FY2026 operating income of $121.8M fell 5.4% year over year, ahead of the -127.5% change in trailing-twelve-month operating income. Sequentially, it rose 5.9% from the prior quarter.

Context

  • Operating income amounted to 3.8% of revenue in FY2025, down 12.2 pp from a year earlier.
  • Operating income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 11 analysts of $888.36M (+460.8%) for the fiscal year ending Dec 2026, a step up from the -122.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$121.8M+5.9% QoQ
Last fiscal yearDec 2025
-$246.2M-122.7% YoY
LTMJun 2026
-$285.6M-127.5% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.4%+132.4%+137.8 pp
1 year-122.7%+460.8%+583.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(246.2M) USD
Year-over-year change
-122.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How AVTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -127.5% is the 8th highest of 9, against a peer median of +6.0%.
  • Operating income amounts to 4.4% of revenue for AVTR, versus a peer median of 14.2%.
AVTR Competitors
Operating Income for AVTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$5.22B USD-2.8%-12.0%20.4%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$686.5M USD+9.8%-6.8%20.6%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$493.8M USD+296.6%-7.9%12.3%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$235M USD+5.1%-17.6%9.1%
STVNStevanato Group S.p.A.LTM Jun 2026€196.53M EUR+6.9%-1.6%16.1%
RGENRepligen CorporationLTM Jun 2026$65.3M USD+373.7%-35.8%8.3%
BLFSBioLife Solutions, Inc.LTM Mar 2026-$10.89M USD-115.5%—10.9%
AZTAAzenta, Inc.LTM Sep 2026-$172.34M USD-2543.7%—27.7%
AVTRAvantor, Inc.LTM Jun 2026-$285.6M USD-127.5%—4.4%
Peer median (excluding AVTR) —+6.0%-10.0%14.2%

Competitors are the stored peer set for AVTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.39B7.51B6.97B6.78B6.55B
Cost of Revenue4.88B4.91B4.6B4.5B4.41B
Gross Profit2.5B2.6B2.36B2.28B2.14B
Gross Margin33.9%34.6%33.9%33.6%32.7%
Research & Development00000
Selling, General & Admin1.53B1.47B1.51B1.64B1.6B
Operating Expenses1.53B1.47B1.67B1.19B2.39B
Depreciation & Amortization379.2M405.5M402.3M405.5M410.2M
EBITDA1.35B1.52B1.1B1.48B138.7M
EBITDA Margin18.3%20.3%15.8%21.8%2.1%
Operating Income972.2M1.13B696.4M1.08B(246.2M)
Operating Margin13.2%15.0%10.0%16.0%-3.8%
Interest Income00000
Interest Expense217.4M265.8M284.8M218.8M169.8M
Other Income / Expenses(219.2M)(279.1M)(285.9M)(230.9M)(195.1M)
Income Before Tax753M851.1M410.5M853.9M(441.3M)
Pre-Tax Margin10.2%11.3%5.9%12.6%-6.7%
Income Tax Expense180.4M164.6M89.4M142.4M88.9M
Net Income572.6M686.5M321.1M711.5M(530.2M)
Net Margin7.8%9.1%4.6%10.5%-8.1%
EPS (Basic)0.861.020.481.05(0.78)
EPS (Diluted)0.851.010.471.04(0.78)
Weighted Avg Shares590.5M650.9M675.6M680.3M678M
Weighted Avg Shares (Diluted)599.6M679.4M678.4M681.9M679.3M

Avantor, Inc.

NYSE:AVTR

Intrinsic Alpha fair value

Locked

Current Price

$15.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.